MindMed Investor Presentation September 2023

MindMed is a neuro-pharmaceutical drug development company focused on developing psychedelic-inspired medicines and non-hallucinogenic derivatives for therapeutic applications. The company's lead program centers on zolunicant, a non-hallucinogenic synthetic derivative of ibogaine. This September 2023 investor presentation covers the company's clinical development pipeline, regulatory strategy, and market opportunity in emerging psychedelic medicine.